Vascular Solutions' thrombus extractor:
This article was originally published in Clinica
Vascular Solutions has received US FDA 510(k) clearance to sell a version of its Pronto extraction catheter that is sufficiently large but also short enough to remove thrombus from haemodialysis grafts and fistulas. The Pronto-Short device will be used to treat the relatively large-sized grafts and fistulas, which are prone to clotting, with patients requiring on average one de-clot procedure each year, according to the Minneapolis, Minnesota firm. The original Pronto device is designed to remove thrombi from arteries. The firm estimates the additional US market opportunity addressed by the Pronto-Short to be around $100m annually.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.